Share on StockTwits

Smith & Nephew plc (LON:SN) was downgraded by research analysts at Morgan Stanley to an “equal weight” rating in a report released on Friday. They currently have a GBX 1,026 ($17.21) price objective on the stock, up from their previous price objective of GBX 980 ($16.44). Morgan Stanley’s price objective would suggest a potential downside of 0.68% from the stock’s previous close.

Other equities research analysts have also recently issued reports about the stock. Analysts at Societe Generale reiterated a “sell” rating on shares of Smith & Nephew plc in a research note on Tuesday, August 5th. They now have a GBX 700 ($11.74) price target on the stock. Separately, analysts at Deutsche Bank reiterated a “buy” rating on shares of Smith & Nephew plc in a research note on Monday, August 4th. They now have a GBX 1,225 ($20.55) price target on the stock. Finally, analysts at Beaufort Securities downgraded shares of Smith & Nephew plc to a “hold” rating in a research note on Monday, August 4th. Two equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and six have given a buy rating to the company. Smith & Nephew plc presently has a consensus rating of “Hold” and an average price target of GBX 983.29 ($16.50).

Shares of Smith & Nephew plc (LON:SN) opened at 1038.00 on Friday. Smith & Nephew plc has a 52-week low of GBX 737.50 and a 52-week high of GBX 1136.00. The stock has a 50-day moving average of GBX 1033. and a 200-day moving average of GBX 966.9. The company’s market cap is £9.280 billion.

Smith & Nephew plc is a global medical devices business operating in the markets for orthopaedic reconstruction and trauma, endoscopy (LON:SN) and advanced wound management.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.